Contact:
4008465777
On November 11, 2021, the 2021 Thinking Finance Annual Investors Meeting and Golden Bridge Awards Ceremony was held in Shanghai. Tonghua Dongbao won the Golden Bridge Award for the Most Valuable Pharmaceutical Company of the Year.
The award winners were determined through a thorough evaluation of their achievements in the past year, investment value, innovation ability, and CSR engagement. The Awards aim to discover the most innovative, promising, and valuable Chinese companies. This honorable title embodies the industry's recognition of Tonghua Dongbao's profitability, innovation ability, and CSR engagement in the last year, as well as the Company's outstanding contribution to diabetes treatment.
In the first three quarters of 2021, Tonghua Dongbao delivered an impressive performance with steadily growing profits. The Company recorded operating revenue of RMB 2.455 billion, up 12.33% YoY, a net profit attributable to the parent company of RMB 1.068 billion, up 41.28% YoY, a net profit excluding non-recurring gains and losses attributable to the parent company of RMB 901 million, up 19.88% YoY. The basic earnings per share (EPS) in Q3 hit RMB 0.19, up 83.72% YoY.